Related Experiment Videos
Phospholipase A2 inhibitors in development
1Department of Preclinical Research, Boehringer Mannheim GmbH, Germany.
Expert Opinion on Investigational Drugs
|March 1, 1997
Summary
Phospholipase A2 (PLA2) inhibitors targeting inflammatory pathways show promise, but challenges like bioavailability and selectivity hinder clinical success for secretory (sPLA2), cytosolic (cPLA2), and Ca2+-independent (iPLA2) isoforms.
Area of Science:
- Biochemistry and Molecular Biology
- Pharmacology and Drug Development
- Inflammation and Immunology
Background:
- Three phospholipase A2 (PLA2) isoforms exist: secretory (sPLA2), cytosolic (cPLA2), and Ca2+-independent (iPLA2).
- sPLA2 and cPLA2 are implicated in releasing arachidonic acid and pro-inflammatory mediators, with cPLA2 being dominant in T-cell-mediated arthritis.
- PLA2-derived lipid mediators have diverse roles in inflammation, including immediate signs, secondary processes (e.g., oxidative stress, apoptosis), and regulating inflammatory gene expression.
Purpose of the Study:
- To review the current landscape of phospholipase A2 (PLA2) inhibitors.
- To highlight the challenges and potential of developing specific inhibitors for sPLA2, cPLA2, and iPLA2 isoforms.
- To identify potential therapeutic applications for PLA2 inhibitors in various inflammatory diseases.
Main Methods:
- Review of existing literature on PLA2 isoforms and their inhibitors.
- Analysis of clinical development status and challenges for sPLA2, cPLA2, and iPLA2 inhibitors.
- Identification of key obstacles in PLA2 inhibitor development, including bioavailability, affinity, and selectivity.
Main Results:
- Numerous secretory (sPLA2) inhibitors have been developed, with a few active site-directed inhibitors showing clinical potential (e.g., BMS-181162, LY311727).
- Currently, no likely clinical candidates are emerging for cytosolic (cPLA2) and Ca2+-independent (iPLA2) inhibitors.
- Significant challenges remain, including insufficient oral bioavailability, low in vivo efficacy due to low affinity, and lack of isoform selectivity.
Conclusions:
- While sPLA2 inhibitors have seen considerable development, cPLA2 and iPLA2 inhibitors require further research for clinical translation.
- Overcoming obstacles in bioavailability, affinity, and selectivity is crucial for the successful development of PLA2 inhibitors.
- PLA2 inhibitors are being investigated for conditions such as sepsis, pancreatitis, inflammatory bowel/skin diseases, asthma, and rheumatoid arthritis.